VALN — Valneva SE

Valneva (VALN) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: EUR 127 million for the first nine months of 2025, up 9% from EUR 112.5 million in the same period of 2024.
• Product Sales: EUR 119.4 million, a 6.2% increase year-over-year.
  • IXIARO sales: EUR 74.3 million (+12.5%).
  • DUKORAL sales: EUR 21.5 million (down from EUR 22.3 million).
  • IXCHIQ sales: EUR 7.6 million (up from EUR 1.8 million).
• Operating Loss: EUR 53.9 million, compared to an operating profit of EUR 34.2 million in the prior year, largely due to the previous year’s sale of a Priority Review Voucher.
• Cash Position: EUR 143.5 million as of September 30, 2025, down from EUR 168.4 million at the end of 2024. Cash used in operating activities decreased significantly to EUR 28.4 million from EUR 76.7 million.
• Adjusted EBITDA: Negative EUR 37.7 million, down from a positive EUR 48.6 million in the previous year.

2. Strategic Updates and Business Highlights

• IXCHIQ: Responded to chikungunya outbreaks with 40,000 doses supplied. However, the product is currently suspended in the U.S. pending FDA feedback.
• Lyme Disease Vaccine (VLA15): Completed vaccinations in the VALOR Phase III study, with results expected in the first half of 2026. Aiming for a product launch in autumn 2027.
• Regulatory Approvals: Secured additional marketing authorizations for IXCHIQ in the U.K. and Brazil, and label extensions for IXCHIQ in Europe and Canada.
• Shigella Vaccine: Positive Phase I/II results reported, with ongoing studies expected to yield pilot efficacy data next year.

3. Forward Guidance and Outlook

• 2025 Guidance: Product sales projected between EUR 155 million and EUR 170 million; total revenues between EUR 165 million and EUR 180 million. R&D expenses expected to be EUR 80 million to EUR 90 million.
• Long-term Outlook: Anticipated sustained profitability post-approval of the Lyme vaccine, with continued growth in established brands and strategic investments in R&D.

4. Bad News, Challenges, or Points of Concern

• IXCHIQ Suspension: The U.S. license suspension remains a significant challenge, with no clear timeline from the FDA for resolution.
• DUKORAL Sales Decline: Sales impacted by currency fluctuations and a transition to a new distributor in Germany, leading to uncertainty in recovery.
• Operating Losses: Significant operating losses reported, raising concerns about financial sustainability without successful product launches.
• Zika Vaccine Development: Uncertainty surrounding funding and regulatory pathways may hinder further investment in the Zika vaccine candidate.

5. Notable Q&A Insights

• FDA Communication: No predefined timeline for FDA feedback on IXCHIQ; Valneva hopes for collaborative dialogue.
• DUKORAL Recovery: Transition to a new distributor in Germany is expected to be a temporary setback, with growth anticipated once the transition is complete.
• Lyme Vaccine Launch: Pfizer's timeline for the Lyme vaccine submission supports the targeted launch for the 2027 tick season, contingent on successful Phase III results.
• Zika Vaccine Funding: Valneva is cautious about advancing the Zika candidate without substantial external funding due to the uncertain return on investment.

This summary encapsulates the key aspects of Valneva's Q3 2025 earnings call, highlighting both the company's progress and the challenges it faces moving forward.